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Highlights
Obesity and excess caloric intake
promotes cancer aggressiveness,
reduces response to chemotherapy
and increases the likelihood of re-
occurrence, yet little is known
about how to better target tumors
in these patients.
Altered metabolism is a common
feature of human cancers. Distinct
metabolic phenotypes are often
caused by a combination of tissue
specific contexts and distinct
genomic alterations of the tumor.
Lipid metabolism represents a
therapeutic opportunity in many
tumor types. To translate these
therapies into the clinic it is neces-
sary to establish robust genomic,
histological and biometric bio-
markers for modulators of lipid
metabolism.
Utilizing diet as a modality to in-
crease therapy efficacy could have
significant effect in some tumors.Obesity is a leading contributing factor to cancer development worldwide. Epidemiological ev-
idence suggests that diet affects cancer risk and also substantially alters therapeutic outcome.
Therefore, studying the impact of diet in the development and treatment of cancer should be
a clinical priority. In this Review, we set out the evidence supporting the role of lipid metabolism
in shaping the tumor microenvironment (TME) and cancer cell phenotype. We will discuss how
dietary lipids can impact phenotype thereby affecting disease trajectory and treatment
response. Finally, we will posit potential strategies on how this knowledge can be exploited
to increase treatment efficacy and patient survival.
Obesity and the Tumor Microenvironment
Excess caloric intake leads to obesity and is a major risk factor for diabetes, cardiovascular disease,
stroke, and incidence of cancer worldwide. Indeed, high body fat is associated with an increased like-
lihood of developing multiple hematological malignancies, and breast, esophageal, renal, colon,
pancreatic, and endometrial cancers [1]. Prospective analysis of 900 000 cancer-free adults in the
US showed that men and women with the highest body mass index (BMI) had a 52% and 62%
increased risk, respectively, of dying from cancer than their normal weight counterparts [2]. Increased
body weight and fat tissue results in altered hormone levels, such as increased estrogen and insulin,
which play major roles in cancer development and can result in systemic metabolic changes; that is,
hyperglycemia (see Glossary; due to insulin resistance) or elevated levels of circulating lipids. Obesity
also promotes tissue inflammation and vascular dysfunction [3]. However, there is limited understand-
ing of the direct impact that diet has on cells within the TME. For example, it is not well known if
elevated blood glucose levels promote the proliferation of cancer cells or if increased lipid availability
in the TME promotes cancer cells to use these lipids as an energy source or substrates for membrane
synthesis.
Epidemiological evidence suggests that diet substantially alters treatment outcome in cancer
patients; that is, meta-analyses show that breast cancer recurrence is 30% higher in obese women
compared to their normal-weight counterparts [4]. Therefore, a better understanding of the effect
of diet, in particular the carbohydrate- and fat-rich western diet, on nutrient availability within the
TME and its impact on signaling pathways that determine drug sensitivity is essential for the devel-
opment of novel anticancer therapies. In this Review, we discuss lipid metabolism within the context
of the TME and explore how diet can impact cancer phenotype, disease trajectory, and treatment
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The synthesis of lipids is a highly coordinated and controlledmolecular program regulated by the ste-
rol regulatory element binding proteins (SREBPs), which respond to upstream signaling networks (i.e.,
PI3K/AKT/mTORC1 pathway) and to the cellular nutrient status (i.e., environment deplete of lipids [5])
to regulate the expression of enzymes involved in cholesterol and fatty acid (FA) synthesis and uptake
[6]. Lipids are a highly diverse class of biological molecules, including FAs, triglycerides, sterols, as
well as phospholipids and glycolipids – the main structural components of biological membranes.
Aberrant lipid metabolism is found in many human cancers, predominantly but not exclusively to
maintain ample production of phospholipids to generate the membranes of cancer cells. De novo
synthesized lipids are also used by cancer cells to generate energy via fatty acid oxidation (FAO)
[7] and are required for post-translational modification of proteins [6] (Figure 1). Altered lipidTrends in Cancer,--, Vol.--, No.-- https://doi.org/10.1016/j.trecan.2019.09.007
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Glossary
Auxotrophic: the requirement of
extrinsic factors, that cannot be
synthesized by an organism, to
support its own growth.
Desmoplasia: growth of connec-
tive tissue, usually associated with
cancer.
High-fat diet (HFD): diet with
levels of fat that are above that of
what is normally consumed.
Hyperglycemia: when a patient
has higher glucose levels in their
bloodstream.
Hypoxemia: when there is
dangerously low levels of oxygen
in arterial blood.
Lipogenesis: metabolic process
of making lipids.
Lipotoxicity: accumulation of
lipids that results in cell dysfunc-
tion and death.
Macropinocytosis: cellular pro-
cess of nonspecific uptake of
extracellular fluid.
Postprandial: time during or after
eating a meal.
Preprandial: time before eating a
meal.
Tissue dysplasia: abnormal
growth and change of a tissue.
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Trends in Cancermetabolism is also associated with oncogenic events in cancer. In lymphoma, amplification of MYC
leads to upregulation of de novo lipogenesis, suggesting it is required for MYC-dependent transfor-
mation and growth [8]. MYC cooperates with SREBPs to regulate lipid synthesis and tumor growth in
multiple cancer types [9]. Clear cell renal cell carcinomas (ccRCCs), characterized by functional loss of
the von Hippel–Lindau (VHL) tumor suppressor that leads to stabilization of the hypoxia inducible
factors (HIFs), show a shift in cellular metabolism where glutamine-derived carbon is almost exclu-
sively used for de novo lipogenesis [10]. Indeed, ccRCCs are histologically defined by the presence
of large organelles that store glycogen and lipids, thus altered lipid metabolism is central to the tu-
mor phenotype [11].
Cancer mutations converge on deregulated metabolism [12] and oncogenic hotspot mutations are
also found in metabolic enzymes. For instance, mutations in IDH occur in low-grade gliomas, second-
ary glioblastomas, and acute myelogenous leukemias (AML) [13,14]. Point mutations in IDH1 lead to
neomorphic activity and production of the oncometabolite 2-hydroxyglutarate (2-HG). Accumulation
of 2-HG alters the activity of oxoglutarate-dependent dioxygenases; several of which control the
methylation state of DNA and histones [15]. Wild-type isocitrate dehydrogenase (IDH) proteins in
cancer can also reductively carboxylate a-ketoglutarate to generate citrate, allowing glutamine-
derived carbon atoms to be shuttled into lipid synthesis, particularly when the activity of the
tricarboxylic acid (TCA) cycle is impaired, such as under hypoxic conditions or in cells with defective
mitochondria [10,16,17]. IDH1 protein expression is also upregulated in primary glioblastomas, with
its inhibition resulting in decreased levels of a-ketoglutarate, reduced NADPH production, and lower
flux of acetate- and glucose-derived carbon into lipids [18]. These metabolic changes are accompa-
nied by altered histonemethylation and differential expression of differentiationmarkers [15,18], sug-
gesting that alterations in metabolic genes not only impact metabolic pathways but can also affect
global gene expression through epigenetic mechanisms.
Specific components of the lipogenic machinery have been shown to play a protumorigenic role in
several cancers. For example, fatty acid synthase (FASN), a key downstream target of SREBP respon-
sible for the NADPH-dependent synthesis of palmitate (Figure 1), is upregulated in breast, prostate,
ovarian, stomach, and colorectal cancers [19]. Increased FASN expression correlates with established
oncogenic events, such as HER2 amplification in breast cancer [20] and PTEN loss in prostate and
ovarian cancers [21,22]. Efforts to efficiently block FASN for cancer treatment have been hampered
by unexpected toxicity and metabolic compensation via lipid uptake [6]. Thus, lipid metabolism is
indispensable for tumor progression and targeting it can be efficacious in cancer, but understanding
the conditions and context that imparts sensitivity to inhibition is key to the development of success-
ful treatment strategies.Environmental Heterogeneity within the TME
Genetic intratumor heterogeneity is central to tumor evolution and drug resistance [23]. However, it is
also clear that solid tumors must contain substantial metabolic intratumor heterogeneity, in part as a
result of gradients of blood-derived nutrients and oxygen delivered by the tumor vasculature into the
TME. Oxygen availability impacts cancer cells, as low oxygen (hypoxia) results in the stabilization and
activation of HIF proteins that drive the transcription of distinct sets of target genes allowing meta-
bolic adaptation. The presence of tumor hypoxia by the histological detection of HIFs, or their down-
stream targets, is associated with a poor clinical outcome in cancer patients, particularly in invasive
tumors of a higher grade or more aggressive stage [24–28]. Moreover, cancer cells that reside in hyp-
oxic environments have increased metastatic capacity, stem-like properties and display chemoresist-
ance [29].
Blood oxygen levels are tightly regulated as hypoxemia results in organ damage and death. In
contrast, levels of circulating nutrients, such as sugars, amino acids, and lipids, can fluctuate signifi-
cantly due to dietary intake; for example, postprandial circulating lipid levels are higher in obesemen
and women compared to their normal weight counterparts [30,31]. If oxygen is limiting within the
TME, due to inadequate vasculature or high proliferative capacity of cancer cells driving demand2 Trends in Cancer,--, Vol.--, No.--
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Figure 1. Intrinsic and Extrinsic Lipid Supply in Cancer.
The central pathways that regulate lipid abundance in cancer cells via de novo lipogenesis, lipid uptake or lipid degradation via fatty acid oxidation (FAO).
De novo lipogenesis and cholesterol biosynthesis are highlighted in yellow. Lipid integrity is modulated by compartmentalization of lipids into lipid droplets
(LDs) and detoxification of oxidative lipid damage via glutathione peroxidase 4 (GPX4). Abbreviations: ACAT, acetyl-CoA acetyltransferase; ACC, acetyl-
CoA carboxylase; ACLY, ATP citrate lyase; ACSS1, acetyl-CoA synthetase; CPT1, carnitine palmitoyltransferase I; FABPs, fatty acid binding proteins;
FASN, fatty acid synthase; G6PD, glucose-6-phosphate dehydrogenase; GCLC, glutamate–cysteine ligase catalytic subunit; GCLM, glutamate-cysteine
ligase modifier subunit; GLS, glutaminase; GLUT1, glucose transporter 1; GSR, glutathione-disulfide reductase; GSS, glutathione synthetase; HMGCR,
hydroxymethylglutaryl-CoA reductase; HMGCS, hydroxymethylglutaryl-CoA synthase; IDH, isocitrate dehydrogenase; LDHA, lactate dehydrogenase A;
LDLR, low density lipoprotein receptor; MCTs, monocarboxylase transporters; PDH, pyruvate dehydrogenase; PHGDH, phosphoglycerate
dehydrogenase; PFK, phosphofructokinase; PSAT1, phosphoserine aminotransferase 1; PSPH, phosphoserine phosphatase; SHMT1, serine
hydroxymethyltransferase 1; SCD, stearoyl-CoA desaturase; SLC1A4, solute carrier family 1 member 4; SLC1A5, solute carrier family 1 member 5;
SLC7A11, solute carrier family 7 member 11; TXNRD, thioredoxin reductase.
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Trends in Cancerabove that of supply, thenmetabolite concentrations also form steep gradients in tumors, resulting in
regions deplete of blood-derived nutrients. As a consequence, populations of cancer cells distant
from the vasculature are under conditions of extreme metabolic stress and could be more sensitive
to fluctuations in circulating nutrient concentrations. Unlike oxygen gradients nutrient gradients
exhibit diurnal tidal-like fluctuations depending on the frequency of food intake and composition
of the diet (Figure 2). Thus, local TME nutrient levels have a substantial impact on tumor phenotype,
particularly in individuals whose circulating nutrient levels are consistently in excess and whoseTrends in Cancer,--, Vol.--, No.-- 3
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Figure 2. Nutrient Availability and Penetrance in the Tumor Microenvironment.
Diagramatic representation of the tumor microenvironment and nutrient gradients that will exist in patients
preprandial (before a meal), postprandial (after a high-fat meal), or in patients who have a sustained high food
intake (green, high nutrient availability; grey, low nutrient availability). In some tumors, metabolic symbiosis with
stromal cells (e.g., cancer-associated fibroblasts or adipocytes) further alters local nutrient availability (regional
green intensity).
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Trends in Cancertumors have a genomic architecture that imparts an auxotrophic phenotype for specific factors; such
as, KRASv12-driven tumors dependent on macropinocytosis to scavenge nutrients from their local
microenvironment [32].
The cellular response to lipid and oxygen depletion is not necessarily distinct. Indeed, SREBPs are
part of an oxygen-sensing pathway in yeast controlling the expression of hypoxia-dependent genes
[33]. In mammalian cancer cells, SREBPs and their downstream targets are upregulated in hypoxia and
essential for cell survival [34,35]. Furthermore, fatty acid desaturases, which are controlled by SREBP,
utilize molecular oxygen as a cofactor for the introduction of double bonds into newly synthesized
FAs [36]. Desaturation is indispensable in cancer to avoid lipotoxicity under conditions of nutrient
stress, be it through dependency on steroyl-CoA desaturase (SCD) or fatty acid desaturase 2
(FADS2) [37,38].
Maintenance of lipid synthesis under hypoxic conditions promotes cancer cell survival but the contri-
bution of glucose-derived carbon to generate citrate and acetyl-CoA via the TCA cycle is compro-
mised, due to the shunting of pyruvate to lactate. Under hypoxia, cancer cells shift the production4 Trends in Cancer,--, Vol.--, No.--
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Trends in Cancerof acetyl-CoA from glucose to glutamine as maintenance of lipid synthesis is essential for cell survival
[16,17]. Indeed, HIF1 activation promotes SIAH2-mediated degradation of OGDN2, resulting in a
shunt of glutamine-derived carbon into FA synthesis [39]. More recently we and others identified
acetyl-CoA synthetase 2 (ACSS2) to be a novel drug target in aggressive breast, brain, prostate, ovary
and lung cancers [40–43]. ACSS2 expression is driven by SREBP2 under metabolic stress [40] and
extracellular acidification [44] allowing for the conversion of acetate to acetyl-CoA for lipid synthesis.
Lipid metabolism is also important in disease recurrence and metastasis formation. Two distinct
murine models of breast cancer (MYC/KRAS and MYC/NEU) showed an upregulation of genes
involved in FA metabolism in tumors treated with neoadjuvant therapy, suggesting it is a common
feature of residual disease [45]. In ovarian cancer, the primary metastatic site is the adipocyte-rich
omentum and adipocytes secrete adipokines coercing cancer cells to selectively metastasize to this
tissue. It has been shown that ommental adipocytes release free FAs that are taken up by ovarian
cancer cells in a fatty acid binding protein 4 (FABP4)-dependent manner for FAO and energy gen-
eration [46].
While enhanced lipid synthesis supports cell growth and proliferation, cancer cells also have to pro-
tect their lipid pools from oxidative damage. In ccRCC cells inhibition of glutathione peroxidase 4
(GPX4), which removes lipid peroxides from membrane lipids, results in the induction of ferroptosis
[47,48]. Generation of membrane lipids containing long-chain polyunsaturated FAs (PUFAs) pro-
motes cancer cell sensitivity towards ferroptosis induction, as inhibition of acyl-CoA synthetase 4
(ACSL4), which preferentially generates PUFA-containing acyl-CoAs, blocks cell death induction after
GPX4 inhibition [49]. Moreover, therapy-resistant cancer cells that have undergone epithelial to
mesenchymal transition (EMT) are dependent on GPX4 for their survival [50]. Thus, maintenance of
a dynamic reservoir of lipids in cancer cells is essential for tumor growth and disease progression
but also causes a selective liability that can be exploited therapeutically.High-Fat Diets and Cancer
As mentioned previously, SREBPs also control serum-derived lipid uptake through regulating the
expression of the low-density lipoprotein receptor (LDLR). In pancreatic cancers and glioblastomas,
SREBPs upregulate LDLR expression, resulting in the enhanced uptake and storage of cholesteryl es-
ters (CEs) in lipid droplets in an acetyl-coenzyme acetyltransferase 1 (ACAT1/SOAT1)-dependent
manner. This results in a positive feedback loop that maintains high PI3K/AKT/mTOR/SREBP activity
and fuels cancer aggressiveness [51,52]. It is likely that cancer cells attempt to fulfill their lipid demand
through lipid uptake as long as lipids are readily available within the TME.
Ras-driven tumors, such as lung adenocarcinomas (LUACs) and pancreatic ductal adenocarcinomas
(PDACs), harbor recurrent activating hotspot mutations in the oncogene K-ras. Ras-transformed cells
exhibit an endocytic phenotype in which they take up and catabolize extracellular proteins to fuel
cellular bioenergetics and growth [32]. This hard-wired dependency results in enhanced sensitivity
towards macropinocytosis inhibitors in K-ras-mutant but not wild-type PDAC xenografts [53]. In addi-
tion, tumor-associated stromal cells present in the TME can be coerced into supporting specific
metabolic phenotypes to aid cancer growth. For example, pancreatic stellate cells (PSCs) undergo
transdifferentiation into cancer-associated fibroblasts (CAFs), resulting in metabolic rewiring and
excretion of lysophosphatidylcholine into the TME, which is then metabolized to lysophosphatidic
acid (LPA) by autotaxin [54]. As LPA is an important lipid mediator, this stromal signaling axis pro-
motes tumor growth and disease progression [54].
While multiple preclinical studies have clearly demonstrated the importance of lipid provision for can-
cer growth, they are mostly performed under standard conditions where the nutritional aspects of a
western diet are not included. It is likely that the metabolic composition of the TME, and heterotypic
cellular relationship of cancer and non-cancer cells within it, will be distinct in cancers arising in indi-
viduals exposed to different diets and nutritional regimens, such as those consuming a high-fat diet
(HFD).Trends in Cancer,--, Vol.--, No.-- 5
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mouse model of sporadic cancer. Mice were generated with inducible RasV12 expression that pro-
duced a mosaic of transformed epithelial cells in the pancreas and small intestine [55]. Mice previ-
ously fed a HFD displayed reduced extrusion of transformed cells from themosaic tissues, suggesting
exogenous lipid supply aided the persistence of transformed cells promoting tissue dysplasia [55].
This could be phenocopied in vitro, where addition of FAs, particularly palmitate, reduced apical
extrusion of epithelial cells from the monolayer in a dose-dependent manner [55]. Moreover, in
several mutant KRas preclinical PDAC models, tumor growth and metastasis were increased in
mice fed a HFD [56,57]. Obesity-induced inflammation was also shown to promote desmoplasia
and immune activation of PSCs and reduce vascular perfusion and drug delivery [56]. Enhanced
adipocyte infiltration caused by obesity also promoted PDAC growth andmetastasis [58] and supple-
mentation with adipose tissue-conditioned medium increased the migratory capacity of cancer cells
in vitro [58]. In another study, the increased PDAC tumor burden of mice fed a HFD translated into a
shorter survival time [59]. In colon cancer, HFD was shown to enhance the number and function of
Lgr5+ intestinal stem cells [60]. Intestinal crypt-derived organoids extracted frommice fed a HFD dis-
played increased regenerative capacity and were less dependent on niche factors generated by Pan-
eth cells for growth. This phenotype was recapitulated by the addition of palmitate to the culture me-
dium, indicating that this lipid is a central component in the regulation of stem cell function [60].
Therefore, local lipid availability within the TME provided by the diet markedly influences the
outcome of oncogene activation and can determine the frequency of tumor formation in different
tissues.
Altering nutrient supply and availability in the TME can also influence disease aggressiveness and
treatment response. Aggressive ovarian, breast and melanoma cancer cell lines were found to
have high expression levels of monoacylgylcerol lipase (MAGL), which regulates the release of free
FAs from neutral lipid stores [61]. While xenografts expressing shRNAs against MAGL showed a
marked reduction in growth, this effect was completely abolished in mice fed an HFD [61]. This is
similar to results obtained for SCD and ACAT1, where sensitivity towards target inhibition was only
seen under nutrient-deplete conditions [37,51]. Currently, it is highly likely that small molecules
that inhibit these promising anticancer targets would initially fail clinical testing and not because
they lack target inhibition potency. Effective targeting of these enzymes would require a combination
strategy that either diminishes the systemic and, as a consequence, TME lipid availability, or blocks
the uptake of local lipids by cancer cells. Future clinical trials have to consider metabolic compensa-
tion and at least record nutritional parameters of their participants. We also need to achieve better
understanding of the complex relationships between tumor genotype, phenotype, and targeted
therapy efficacy and translate this insight into clinical practice.Complex Synthetic Lethality in Targeting Cancer
Despite the clinical success of PARP inhibitors in BRCA-mutant cancers, identifying other synthetic
lethalities that have transitioned to the clinic has so far been limited. This could be due to the TME
not imparting sensitivity to the targeted therapy. For instance, HIF2 inhibitors are efficacious in
ccRCCs due to the loss of functional VHL resulting in the upregulation of HIF proteins [62]. In other
tumor types that have not lost VHL, the efficacy of HIF2 inhibitors is dependent on the presence of
tumor hypoxia or other factors elevating HIF2 expression and dependency. This suggests that if
tumors alter their vasculature to increase oxygen supply, such as switching to a co-optive rather
than a neoangiogenic phenotype [63], HIF expression decreases and drugs targeting HIF2 are no
longer efficacious. Indeed, tumors switching to co-option is a mechanism of resistance to antiangio-
genic therapy in liver metastases [63]. Thus, complex synthetic lethality marks the TME as being
essential for the targeting of cancer-specific dependencies that can be exploited in vivo and ulti-
mately in patients (Figure 3).
To date, there are limited studies that have sought to specifically identify novel anticancer targets in
obese patients, with the exception of the study by Zaytouni et al., which shows that silencing of argi-
nase 2 (ARG2) in orthotopic PDAC tumors is more efficacious in obese mice [64]. In human PDAC6 Trends in Cancer,--, Vol.--, No.--
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Figure 3. Exploiting the Nutrient Status of Cancer Cells for Cancer Therapy.
Diagramatic representation of the tumor microenvironment and nutrient gradients in patients who have a normal
body weight, who consume a high-fat diet (HFD) or who are obese. Also included is the impact of antiangiogenic
therapy on intratumoral nutrient gradients (green, high nutrient availability; grey, low nutrient availability). For each
environmental condition dictated by nutrient status strategies on how these can be exploited therapeutically are
shown. Abbreviations: ACSS2, acetyl-CoA synthetase 2; ARG, arginase; HIF, hypoxia-inducible factor.
Please cite this article in press as: Peck and Schulze, Lipid Metabolism at the Nexus of Diet and Tumor Microenvironment, Trends in Cancer
(2019), https://doi.org/10.1016/j.trecan.2019.09.007
Trends in Cancersamples, higher ARG2 protein expression is correlated with higher BMI [64], suggesting that PDAC
tumors in obese patients are also more dependent on ARG2, establishing this enzyme as a novel
target in obesity-associated pancreatic cancers (Figure 3). However, tumors with constitutive activa-
tion of AKT are also sensitive to ARG2 depletion, despite being unaffected by an HFD [64].
In prostate cancer, expression of the FA receptor CD36, a transmembrane protein that regulates the
import of long chain FAs, is associated with poor relapse-free survival [65]. Inactivation of CD36 in a
pten/ murine prostate cancer model slowed cancer progression, and treatment with a CD36-tar-
geting antibody reduced tumor growth in patient-derived xenografts (PDXs) [65]. Moreover, metas-
tasis-initiating subpopulations of oral squamous cancer cells, defined by their slow proliferation and
high expression of the stem cell marker CD44, have high expression of CD36 and an increased capac-
ity to uptake and metabolize FAs [66]. Mice injected with this subpopulation of cells fed a HFD pre-
sented with a higher frequency of lymph node metastases [66]. A similar phenotype could be phe-
nocopied by exposing cancer cells to palmitate prior to implantation. Crucially, mice treated with
the monoclonal antibody JC63.1, which blocks the transport activity of CD36, displayed reduced
metastasis formation [66]. Together, these studies highlight that extrinsic supply of lipids, particularly
the FA palmitate, is essential for metastasis development in a CD36-dependent manner. Thus, this
metabolic dependency could be exploited therapeutically and be more efficacious in obese patients
(Figure 3).
Dietary Restriction and Cancer
As outlined above, specific genetic alterations that drive cancer development result in complexmeta-
bolic alterations that not only affect the metabolic network within cancer cells but can also influence
metabolism at the organismal level. Thus, distinct cancers can be considered metabolic diseases un-
der this context, suggesting that aggressiveness and, more importantly, response to therapy could
be impacted by dietary modulation or supplementation.Trends in Cancer,--, Vol.--, No.-- 7
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Trends in CancerLessons on systemic metabolic interventions can be learned from rare genetic disorders like the
congenital GLUT1 deficiency syndrome, which is caused by impaired glucose transport across the
blood–brain barrier due to mutations in the transporter SLC2A1. Children with this disorder develop
epilepsy and acquired microcephaly and display developmental delay [67]. To circumvent depen-
dency on glucose metabolism patients were put onto a long-chain triglyceride ketogenic diet. After
5.5 years, 10 of 15 patients were seizure free with no serious adverse effects reported [68], highlighting
that dietary modulation can elicit positive and durable responses to disease burden. A similar
approach in cancer is needed to be developed in the clinic, particularly for those patients who may
be at high risk of disease recurrence and whose tumors have a hard-wired metabolic architecture.
Indeed, there is mounting preclinical evidence to suggest that altering specific components of a
diet can reduce tumorigenesis. For example, restriction of the amino acid glycine prevents hepatic
carcinoma growth while not affecting the formation of preneoplastic foci in mice [69], with a similar
outcome being observed in the B16 murine melanoma model [70]. In genetically engineered Apc-
driven intestinal cancers and Myc-driven lymphomas, serine and glycine dietary restriction resulted
in increased survival, while only a limited effect was observed in a K-ras-driven model of pancreatic
cancer, suggesting that tumors with an intrinsic capacity for de novo serine synthesis are insensitive
to perturbations in extrinsic supply [71]. In KRASG12A and NRASQ61K PDXs models, methionine restric-
tion significantly reduced tumor growth and increased the sensitivity to 5-fluorouracil, an inhibitor of
pyrimidine nucleotide synthesis. Crucially, the authors show that dietary methionine restriction in a
cohort of healthy humans also results in reduced levels of circulating methionine, cysteine and gluta-
thione, comparable to the observations made in the murine models [72].
While these results show that selectively removing specific amino acids from the diet is feasible in
reducing nutrient availability in patients, the complexity and flexibility of lipid metabolism may be
more challenging. As suggested by multiple preclinical studies, a HFD not only enhances cancer
risk but also promotes cancer aggressiveness. Thus, when an obese patient arrives in the clinic, the
opportunity to implement long-term dietary intervention to reduce cancer risk has passed and typi-
cally they present with a tumor of a higher grade or later stage. Therefore, it is critical to be able to
modulate a patient’s diet to impede tumor growth in an acute intervention or adjuvant setting to pre-
vent recurrence and increase response to therapy. In a mouse model of melanoma obesity has been
shown to increase tumor progression [73]. This effect was particularly potent in BRAF V600E-driven
tumor xenografts, as mice fed a HFD reached twice the size of those on a normal diet [74]. Crucially,
sensitivity to the chemotherapeutic drug dacarbazine was reinstated by switching HFD mice onto a
normal diet or when treated in combination with lipid-lowering agents, such as dehydroacetic acid
or orlistat [74,75]. In tumors that are dependent on lipogenesis we postulate that the histological
scoring of markers of lipid synthesis and uptake, such as FASN and CD36, in tumor tissue could
aid patient stratification, particularly when considering altering dietary lipids in cancer patients
receiving therapy.
It has been shown that a ketogenic diet, that is, a diet low in carbohydrates and high in fat but with the
same caloric intake, improves the efficacy of PI3K inhibitors in a preclinical PDACmodel [76]. This was
achieved by suppression of a feedback loop, by which PI3K inhibition leads to increased production
of insulin, thereby activating the PI3K/AKT signaling pathway despite the presence of the inhibitor.
Enhanced production of insulin is reduced by a ketogenic diet, which prevents postprandial surges
in blood glucose [76]. A ketogenic diet was also shown to have efficacy in preclinical models of glio-
blastoma, slowing the growth of PDXs [77]. A combination of a calorie-restricted and ketogenic diet
also reduced glioblastoma growth, with a significant enhancement in antitumor effect observed when
combined with the glutamine antagonist 6-diazo-5-oxo-L-norleucine [78].
These data show clearly that specific dietary modulations are dependent on the genetic and environ-
mental architecture of tumors. Thus, robust predictive genetic and histological biomarkers are
indispensable for patient stratification for targeted therapy. This must be supplemented with
detailed information about nutritional status, diet, and lifestyle of individual patients. Without this in-
formation, it is not possible to successfully translate any dietary modulation into the era of personal-
ized medicine.8 Trends in Cancer,--, Vol.--, No.--
Outstanding Questions
Are histological and genomic bio-
markers for specific dietary regimes
robust?
Are there available therapies – not
used as first line treatment – that
might be more effective in over-
weight patients?
Is there epidemiological evidence
that suggest acute dietary change
in cancer patients can improve
response to therapy?
Is patient compliance for specific
dietary modulations (e.g., keto-
genic diet) an issue that could
affect treatment response?
Are there chemical mimetics of di-
etary regimes that could be used
instead to circumvent compliance
issues and increase treatment effi-
cacy?
Should population-specific effects
be considered when prescribing
dietary modulation to cancer pa-
Please cite this article in press as: Peck and Schulze, Lipid Metabolism at the Nexus of Diet and Tumor Microenvironment, Trends in Cancer
(2019), https://doi.org/10.1016/j.trecan.2019.09.007
Trends in CancerConcluding Remarks
The development and clinical testing of novel anticancer agents that show promising preclinical ef-
ficacy is a challenging process, in which initial patient benefit observed in small trials is often not
reproducible in larger trials [79]. This lack of reproducibility could be explained in part by the differ-
ences between preclinical models in the laboratory and tumors in patients. Understanding how the
genetic architecture of tumors cooperates with the cellular and metabolic composition of the TME
to determine phenotype is crucial to discovering these novel vulnerabilities. In particular, successful
therapeutic strategies have to take into account the complex relationships between different cell
populations within the TME that are subject to dynamic changes in nutrient supply, particularly in
response to therapy. Furthermore, we need to apply the full repertoire of the clinical toolkit, such
as robust genetic, histological, or biometric imaging biomarkers, allowing patient stratification and
temporal monitoring of treatment response. Indeed, the lack of viable biomarkers for targeted ther-
apies that could be more efficacious in patients with a higher BMI or in patients that follow specific
dietary regimens is amongst the biggest challenges we face in translating preclinical findings on
metabolic vulnerabilities into clinical effect (see Outstanding Questions). Embracing this environ-
mental heterogeneity with scientific rigor is the only route to clinical progress and the ultimate
goal of improving cancer therapy and patient outcome.
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